Amgen Overview

  • Founded
  • 1980
Founded
  • Status
  • Public
  • Employees
  • 24,200
Employees
  • Stock Symbol
  • AMGN
Stock Symbol
  • Investments
  • 60
  • Share Price
  • $234.36
  • (As of Monday Closing)

Amgen General Information

Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Contact Information

Website
www.amgen.com
Formerly Known As
Applied Molecular Genetics
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320
  • United States
+1 (805) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amgen Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$234.36 $232.91 $198.64 - $261.00 $130B 557M 3.15M $10.34

Amgen Financials Summary

In Thousands,
USD 		TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 151,375,930 151,375,930 155,779,207 152,177,826
Revenue 25,979,000 25,979,000 25,424,000 23,362,000
EBITDA 11,142,000 11,142,000 12,835,000 12,462,000
Net Income 5,893,000 5,893,000 7,264,000 7,842,000
Total Assets 61,165,000 61,165,000 62,948,000 59,707,000
Total Debt 33,309,000 33,309,000 32,986,000 29,903,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amgen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amgen‘s full profile, request access.

Request a free trial

Amgen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer suppo
Biotechnology
Thousand Oaks, CA
24,200 As of 2021
00.000
000000000000 00.000

000000

t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons
0000000000000
Cambridge, MA
0000 As of 0000
000.00
000 0000-00-00
0&0

000000 0

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
000000000000000
Foster City, CA
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amgen Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biogen Formerly VC-backed Cambridge, MA 0000 000.00 0&0
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
000000000 00000000 Formerly VC-backed Tarrytown, NY 00000 00000 00000000000 00000
0000000 Formerly VC-backed Boston, MA 0000 000000&0
000000 Formerly VC-backed Bothell, WA 0000 00.000 000000000 00.000
You’re viewing 5 of 8 competitors. Get the full list »

Amgen Patents

  • 11,478

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 485

    Granted

  • 199

    Pending

  • 000

    Expiring in next 12 mo

Amgen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210324331-A1 Process for generating genetically engineered autologous t cells Pending 15-Apr-2020 0000000000
US-20210324333-A1 Method for enhancing production of genetically engineered autologous t cells Pending 15-Apr-2020 0000000000
US-20210316075-A1 Drug delivery devices and associated heating and/or cooling devices Pending 13-Apr-2020 000000000
US-20210261297-A1 Containers and systems for use during external sterilization of drug delivery devices Pending 24-Feb-2020 000000000
US-20210213210-A1 Needle shield removers, drug delivery devices, and related methods Pending 13-Jan-2020 A61M5/3204
To view Amgen’s complete patent history, request access »

Amgen Executive Team (92)

Name Title Board Seat Contact Info
Robert Bradway Chief Executive Officer & Chairman
Peter Griffith Executive Vice President and Chief Financial Officer
Nkem Ogbechie Global Product General Manager
Linda Louie Chief Accounting Officer, Accounting & Vice President
Nancy Grygiel Senior Vice President & Chief Compliance Officer, Legal
You’re viewing 5 of 92 executive team members. Get the full list »

Amgen Board Members (23)

Name Representing Role Since
000 00000 Self Board Member 000 0000
00000 000000 00 Self Board Member 000 0000
0000000 000000 00. Self Board Member 000 0000
00000 0000000 Self Board Member 000 0000
0000 0000000 Amgen Board Member 000 0000
You’re viewing 5 of 23 board members. Get the full list »

Amgen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amgen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amgen‘s full profile, request access.

Request a free trial

Amgen Investments & Acquisitions (60)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 19-Oct-2021 0000000000 00000 Biotechnology 00000 000
0000000 07-Oct-2021 00000 0000 00000 Drug Discovery 00000 000
000000 000000 24-Sep-2021 0000 00000 Drug Discovery
000000000 000 16-Apr-2021 0000000000 00.00 Drug Discovery 000000 00
Rodeo Therapeutics 30-Mar-2021 Merger/Acquisition 00000 Drug Discovery 0000000 0
You’re viewing 5 of 60 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Amgen Subsidiaries (8)

Company Name Industry Location Founded
Amgen Astellas BioPharma Drug Discovery Tokyo, Japan 2013
00000 00000000 Corporate Venture Capital Thousand Oaks, CA 0000
00000 000000 000 0 Foundation Lenexa, KS 0000
000000 00000000 Biotechnology Reykjavik, Iceland 0000
00000 000000 00000 Corporate Pension Thousand Oaks, CA 0000
You’re viewing 5 of 8 subsidiaries. Get the full list »

Amgen Exits (14)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 25-Nov-2020 00 000000000000000 00000 Completed
  • 22 buyers
00000000 23-May-2019 00000 0000 Completed
  • 2 buyers
000000 00000000 00 18-Oct-2018 000000000 000.00 Completed
  • 00000
00000000 04-Oct-2017 00000 00000 00 0000 Completed
  • 6 buyers
Dezima Pharma 14-Oct-2015 Merger/Acquisition 00.000 Completed
You’re viewing 5 of 14 exits. Get the full list »